Moreover, we performed a proof-of-concept experiment to show that the recurrent Kras G12D mutation observed in metastatic lesions from two PyMT mice increases the metastatic efficiency of mouse mammary cancer cell lines in an orthotopic implantation model. This evidence concerns the gene KRAS and breast cancer.